Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2025)

Lexaria Bioscience's Operating Expenses history spans 9 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 45.21% year-over-year to $1.6 million; the TTM value through Nov 2025 reached $11.3 million, up 44.71%, while the annual FY2025 figure was $12.6 million, 102.56% up from the prior year.
  • Operating Expenses for Q4 2025 was $1.6 million at Lexaria Bioscience, down from $2.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $3.9 million in Q2 2025 and bottomed at $813005.0 in Q1 2024.
  • The 5-year median for Operating Expenses is $1.9 million (2021), against an average of $2.0 million.
  • The largest annual shift saw Operating Expenses soared 1473.34% in 2021 before it crashed 71.14% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $2.0 million in 2021, then fell by 11.65% to $1.8 million in 2022, then dropped by 27.67% to $1.3 million in 2023, then soared by 123.39% to $2.9 million in 2024, then crashed by 45.21% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Operating Expenses are $1.6 million (Q4 2025), $2.9 million (Q3 2025), and $3.9 million (Q2 2025).